Publication: 3800

Publication: 3800

Daratumumab (DARA) + Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple MyNewly diagnosed multiple myeloma, daratumumab, autologous stem cell transplanteloma (NDMM): Final Analysis of GRIFFIN

URL

Google Scholar

Citation:: OAB-057

Meeting Instance:: IMS 2022
Year:: 2022
Type:: Abstract
Sub type:: Oral
Funding:: AFT
Endpoint:: No-Endpoint
Analysis:: Other
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Janssen
Grants:

Corr. Author:
Authors:: Douglas W. Sborov Jacob Laubach Jonathan L. Kaufman Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J. Costa Larry D. Anderson Jr. Nitya Nathwani Nina Shah Naresh Bumma Sarah A. Holstein Caitlin Costello Andrzej Jakubowiak Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Huiling Pei Annelore Cortoos Sharmila Patel Thomas S. Lin Paul Richardson Saad Z. Usmani Peter M. Voorhees

Networks:: CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, NY021, OR013

Study: AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Newly diagnosed multiple myeloma, daratumumab, autologous stem cell transplant